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Abstract
Background: The T-helper (Th)1/Th2 dichotomy dominated the field of immune regulation until interleukin
(IL)-17-expressing T cells (Th17) were proposed to be a third lineage of helper T cells, the key players in the
pathogenesis of autoimmune disorders. Autoimmunity to brain tissue may play a pathogenic role in autism.
IL-17A is a pro-inflammatory cytokine that has been shown to play an important role in various autoimmune
neuroinflammatory diseases. The aim of this study was to measure serum levels of IL-17A in relation to the
degree of the severity of autism.
Methods: Serum IL-17A levels were measured by ELISA in 45 children with autism and 40 matched healthy
controls.
Results: Children with autism had significantly higher serum IL-17A levels than healthy controls (P <0.001), with
increased serum levels of IL-17A found in 48.9% of the autism group. Patients with severe autism had significantly
higher serum IL-17A levels than those with mild to moderate autism (P= 0.01), and raised serum IL-17A levels
were significantly more common in children with severe autism (67.9%) than in those with mild to moderate
autism (17.6%), P= 0.001.
Conclusions: Serum IL-17A levels were raised in the group with autism, and the levels correlated significantly
with the severity of autism. This is the first study to measure levels of IL-17A in relation to the severity of autism,
to our knowledge. Further research, with a larger subject population, is warranted to determine whether the
increase of serum IL-17A levels plasma has a pathogenic role in autism, and whether anti- IL-17A therapy could
be useful
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Background
CD4-positive T lymphocytes play a major role in the
regulation of adaptive immunity. Upon activation by
antigen-presenting cells (APC), naive antigen-specific
CD4+ T cells differentiate into different subsets of T
cells. In addition to the classic T-helper (Th)1 and Th2
cells, several novel effector T cell subsets have been re-
cently identified, including Th17 cells [1].
Th1 and Th2 cells are differentially induced, and regulate
immunity against intracellular and extracellular pathogens,
respectively. They are also involved in immune pathologies
such as autoimmunity and allergy [2,3]. Th17 cells have
been shown to induce host protection against extracellular
pathogens and tissue inflammation [4-6], and are thought
to play a key role in autoimmune diseases, including the tis-
sue injury associated with these conditions [7,8].
Th17 CD4 T cells are characterized by production of the
cytokines interleukin (IL)-17A (IL-17) and IL-17 F, and
IL-21 and IL-22 [9]. Since their discovery in 2003, there
have been numerous studies on Th17 cells, and they have
emerged as key players in the pathogenesis of some auto-
immune neuroinflammatory diseases and other auto-
immune disorders traditionally attributed to Th1 cells.
This may be attributable to the induction of neutrophil-
recruiting chemokines (chemokine (C-X-C motif) ligand
(CXCL)1, CXCL2, CXCL8) by IL-17 [10,11].
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Autoimmunity may have a role in the pathogenesis
of autism in a subgroup of patients. Brain-specific auto-
antibodies have been found in some children with
autism [12-18], and there is also an increase in the
frequency of autoimmune disorders in autistic families
[19-26]. Although the origins of autoimmunity in autism
are unknown, it is thought that the major histocom-
patibility complex genes and their products might be
involved [23,27,28].
In this study, we aimed to measure serum IL-17A
levels in a group of children with autism, and to examine
the relationship between serum levels of IL-17A and the
degree of the severity of autism.
Methods
Ethics approval
The local ethics committee of the Faculty of Medicine,
King Saud University, Riyadh, Saudi Arabia, approved
the study, and informed written consent for participation
in the study was signed by the parents or the legal guar-
dians of the participants.
Study population
This was a cross-sectional study, which recruited chil-
dren with autistic disorder from the Autism Research
and Treatment Center, King Khalid University Hospital
(Riyadh, Saudi Arabia). Patients fulfilled the criteria of
the diagnosis of autism based on the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
[29]. Patients with associated neurological diseases (such
as cerebral palsy and tuberous sclerosis) and metabolic
disorders (such as phenylketonuria) were excluded form
the study.
In total, 45 children (36 male, 9 female; age (mean ±
SD) = 8.44 ± 1.73 years, range 6 to 11 years) were en-
rolled in the study group.
The control group comprised 40 age- and sex-
matched, apparently healthy children (32 male, 8 female;
age (mean ± SD) = 8.33 ± 1.72 years, range 6 to 11).
These children were the healthy older siblings of healthy
infants who were attending the Well Baby Clinic at King
Khalid University Hospital for routine follow-up of their
growth parameters. The control children were not
related to the children with autism, and had no clinical
indications of infectious disease or neuropsychiatric dis-
orders. They included none of the enrolled patients with
autism and healthy control children had any clinical
indications of autoimmune disorders such as arthralgia,
arthritis, fever of unknown origin, shin rash, purpuric
eruption, photosensitivity, excessive hair loss, hematuria
or oliguria. All subjects had normal results for urine
analysis and erythrocyte sedimentation rate.
Study measurements
Clinical evaluation of autistic patients
Evaluation of the study group was based on clinical
history-taking from caregivers, and on clinical examin-
ation, and neuropsychiatric assessment of the patients.
In addition, the degree of the disease severity was
assessed by the Childhood Autism Rating Scale (CARS)
[30] which rates the child on a four-point scale in each
of fifteen areas (relating to people; emotional response;
imitation; body use; object use; listening response; fear
or nervousness; verbal communication; non-verbal com-
munication; activity level; level and consistency of intel-
lectual response; adaptation to change; visual response;
taste, smell and touch response; and general impres-
sions). A score of 30 to 36 points on this scale indicates
mild to moderate autism (n = 17), and a score of 37 to
60 points indicates severe autism (n = 28).
Assessment of serum interleukin-17A levels
Serum levels of IL-17A were evaluated using an ELISA
kit (R & D Systems, Inc. 614 McKinley Place NE, Min-
neapolis, MN 55413, USA) designed to measure human
IL-17A in serum. Blood samples were collected from
each studied subject; 2 mL of blood were placed into a
dry clean tube and left to clot at room temperature, then
separated by centrifugation for 15 minutes. The serum
was removed and stored at −20°C until required.
Repeated freeze–thaw cycles were avoided to prevent
loss of bioactive substances.
Microtiter strips coated with a monoclonal antibody
specific for IL-17A were used. Samples, including stan-
dards of known IL-17A concentrations were placed in
the wells of these strips. Two hundred uL of IL-17A
antigen were added to the wells, and the strips were
incubated for 30 minutes at room temperature. Strips
were washed for 3 times in 400 ul of wash buffer then a
biotinylated monoclonal antibody specific for IL-17A
was added and the plate was incubated for one hour at
room temperature. Streptavidin peroxidase was then
added. After incubation and washing to remove all un-
bound enzyme, a substrate solution (color reagents A
and B mixed together in equal volumes within 15 min-
utes of use) that acts on the bound enzyme was added
to induce a colored reaction product, the intensity of
which is directly proportional to the concentration of
IL-17A present in the sample. To increase accuracy, all
samples were analyzed twice in two independent experi-
ments to assess interassay variations and to ensure re-
producibility of the results (P >0.05). No significant
crossreactivity or interference was seen.
Statistical analysis
The results were analyzed by commercially available
software package (Statview, Abacus Concepts Inc.,
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Berkley, CA, USA). The data were non-parametric,
thus they are presented as median and interquartile
range (IQR; 25th to 75th percentile). Patients were
considered to have raised serum IL-17A if the levels
were above the highest cut-off values (1.73 pg/ml),
which was the 95th percentile of the serum IL-17A
levels of healthy controls, as the distribution of the
data was non-parametric. The Mann–Whitney test was
used for comparison between these data, and the χ²
test was used for comparison between qualitative vari-
ables of the studied groups. Spearman’s rho correlation
coefficient ‘r’ was used to determine the relationship
between different variables. For all tests, P <0.05 was
considered significant.
Results
Children with autism had significantly higher serum
IL-17A levels than healthy controls (P <0.001(Table 1,
Figure 1). Increased serum IL-17A levels were found
in 48.9% (22/45) of the patients with autism.
Patients with severe autism had significantly higher
serum IL-17A levels than children with mild to moderate
autism (P=0.01) (Table 1, Figure 2), and the frequency of
increased serum IL-17A levels was significantly higher in
children with severe autism (19/28; 67.9%) than in patients
with mild to moderate autism (3/17; 17.6%) (P=0.001).
There was no difference in serum IL-17A with regard
to gender (median (IQR) = 1.82 (0.9) pg/ml for males
and 1.7 (5.2) ng/ml for females; P= 0.32) or age of the
children with autism (P= 0.32).
Discussion
Th17 cells have been implicated in the pathogenesis of
autoimmune disease, findings supported by recent clin-
ical trials using anti-IL-17 in the treatment of these dis-
eases [31]. Th17 cells are characterized by their
production of IL-17 cytokines, which control the inflam-
matory responses by triggering the secretion of pro-
inflammatory cytokines and chemokines [5,32].
In our series, children with autism had significantly
higher serum IL-17A levels than healthy controls
(P <0.001). Raised serum IL-17A levels were found in
48.9% (22/45) of the patients with autism. A recent
study reported significantly higher plasma concentra-
tions of IL-17 in 28 male subjects with high-functioning
autism spectrum disorder (ASD) compared with 28
Table 1 Serum levels of IL-17A in autistic children and
their relation to the severity of autism
Serum IL-17A (pg/ml), Z score
median (IQR) P value
Healthy children (n = 40) 0.77 (0.8) 6.4
Patients with autism
(n = 45)






autism (n = 28)
2.05 (2.3) (0.01)
IL, interleukin.
Figure 1 Serum levels of IL-17A in autistic patients and healthy
children. Median value for each group is shown by a horizontal bar.
Figure 2 Serum levels of IL-17A in relation to the degree of the
severity of autism. Median value for each group is shown by a
horizontal bar.
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matched controls, and the patients with ASD also had
higher plasma concentrations of other cytokines such as
IL-1 receptor antagonist, IL-1β, IL-5, IL-8, IL-12 and
IL-13 compared with controls. The authors suggested
that abnormal immune responses, as assessed by multi-
plex analysis of cytokines, might be a biological trait
marker for ASD [33]. Another study investigated the cel-
lular release of IL-17 and IL-23 after in vitro immuno-
logical challenge of peripheral blood mononuclear cells
from children with ASD compared with age-matched,
typically developing, controls, and found that the con-
centration of IL-23, but not IL-17, was significantly
reduced in ASD compared with controls. Those authors
recommended that decreased cellular IL-23 production
in ASD warrants further research to determine its role
in the generation and survival of Th17 cells, a cell subset
important in neuroinflammatory conditions that may in-
clude ASD [34].
IL-17A is a pro-inflammatory cytokine that is pro-
duced by a number of human immune cells, including
Th17 cells, neutrophils, and peripheral blood mono-
nuclear cells. Studies have shown that IL-17A is upregu-
lated and involved in the pathogenesis of various
autoimmune inflammatory diseases such as rheumatoid
arthritis, systemic lupus erythematosus, and systemic
sclerosis [35-38]. In addition, IL-17A has been shown to
play an important role in various autoimmune neuroin-
flammatory diseases such as multiple sclerosis (MS) and
experimental autoimmune encephalomyelitis (EAE) [39].
In immune responses against infection and models of
autoimmune diseases, Th1 and Th17 cells often develop
simultaneously [3].The differentiation of Th1 or Th17
cells occurs after exposure to APC-derived polarizing
cytokines such as IL-12 for Th1 cells [40] and trans-
forming growth factor-β, IL-1β, IL-6 and IL-23 for Th17
cells [5,41-43]. These polarizing cytokines further induce
the expression of the transcription factors T-bet or retin-
oic acid receptor-related orphan receptor (ROR)γt and
RORα for Th1 and Th17 differentiation respectively
[44,45]. Dendritic cells (DCs), which are activated by sig-
nals from pathogen-associated recognition receptors,
recognize components of intracellular pathogens [46],
induce the production of polarizing cytokines, and drive
generation of Th17 responses. Consistent with these
findings, Th17 cells have a role in immunity against
intracellular pathogens. In addition, a clear role for
IL-17 in generation of chemokine responses, induction
of anti-microbial proteins and recruitment of neutro-
phils for control of extracellular pathogens has emerged
[47]. The pro-inflammatory actions of Th17 cells ,both
in the clearance of various pathogens and in auto-
immunity, may occur through the induction of
neutrophil-recruiting chemokines (CXCL1, CXCL2,
CXCL8) by IL-17 [10,11].
This study is the first to measure serum IL-17 in rela-
tion to the disease severity in children with autistic dis-
order, to our knowledge. A few previous studies
measured serum IL-17 in children with ASD, but these
studies did not correlate serum IL-17 levels with the de-
gree of severity of autism. In the present study, we found
that patients with severe autism had significantly higher
serum IL-17A levels than children with mild to moder-
ate autism, P= 0.01I, and children with severe autism
were also significantly more likely to have increased
serum IL-17A (67.9%) than patients with mild to moder-
ate autism (17.6%) (P= 0.001). This may indicate that
the extent of the increase in serum IL-17A levels is
closely linked to the degree of the severity of autism.
However, it is not clear whether the increase in serum
IL-17A levels is a mere consequence of autism or has a
pathogenic role in the disease.
CD4+ CD25high regulatory T-cells (Tregs) play an im-
portant role in the establishment of immunological self
tolerance and thereby, in the prevention of autoimmun-
ity [48]. Tregs can suppress Th17 cells and autoimmun-
ity, as activation of Th17 cells can start tissue
inflammation [49]. A recent study reported deficiency of
Tregs in 73.3% of children with autism [25], an dthus,
Deficiency of Tregs may be one of the reasons behind
the activation of Th17 cells and the elevation of serum
IL-17 A levels in children with autism. Osteopontin is a
key pro-inflammatory mediator that may serve to per-
petuate and amplify the inflammatory process in many
autoimmune neuroinflammatory disorders such as EAE
in mice and MS in humans [50]. The Th17-related re-
sponse in humans is enhanced by osteopontin, which
may contribute to the pro-inflammatory actions of Th17
cells in the clearance of pathogens and in autoimmunity
[10,11]. A recent study reported increased serum osteo-
pontin levels in 80.95% of children with autism [51].
Thus, increased serum osteopontin levels in autism may
be another contributing factor to the elevation of serum
IL-17A levels in children with autism.
Autoimmunity to brain tissue may have a pathogenic
role in autism [52-55], as indicated by the presence of
brain-specific auto-antibodies in some children with aut-
ism [12-18]. Levels of IL-12 and interferon (IFN)-γ have
been reported to be significantly increased in patients
with autism [56]. It was suggested that increased IL-12
and IFNγ may indicate stimulation of Th1 cells patho-
genetically linked to autoimmunity in autism [56]. Re-
cently, increased pro-inflammatory Th1 cytokines were
reported to be associated with greater impairments in
core features of autism [57]. Macrophages and DCs ex-
press IL-17A receptors, and can respond to IL-17, pro-
ducing cytokines and chemokines [58,59]. These data
suggest that IL-17 responses can regulate the induction
and generation of Th1 responses. The mechanism by
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which IL-17 regulates the Th1 pathway seems to be via
induction of IL-12 and IFN-γ in APCs. After IL-17
stimulation, DCs and macrophages produce IL-12 and
IFN-γ, respectively. IL-17-dependent-DC-derived IL-12
was able to drive the differentiation of naive T cells into
Th1 cells, and IL-17-dependent macrophage-derived
IFN-γ was able to activate macrophages for control of
intracellular pathogens [59]. Because IL-17A is a stimu-
lator of pro-inflammatory cytokines, IFN-γ and IL-12
[59], it could be the inducer of the Th1 response that
has been reported previously to be linked to auto-
immunity in autism [56]. In addition, the possible role of
IL-17A in induction of the production of brain auto-
antibodies may be associated with induction of the pro-
duction of neutrophil-recruiting chemokines [10,11].
Moreover, osteopontin, which was recently reported to
be increased in many children with autism [51], induces
myelin antigen-specific IL-17 production from Th17
cells via specific osteopontin receptors (β3 integrin
receptors) on T cells [50].
IL-17A was reported to have a possible role in some
autoimmune neuroinflammatory diseases [39], thus the
increased serum levels of IL-17A found in our study
may be a possible contributing factor to the increased
frequency of the brain-specific auto-antibodies in some
children with autism. Further research is warranted to
determine the possible link between increased serum
levels of IL-17A and the presence of brain-specific auto-
antibodies in some children with autism.
Conclusions
In this study, we found that serum IL-17A levels were
increased in some children with autism, and were sig-
nificantly correlated with the severity of autism. How-
ever, further research, with a larger subject population, is
warranted to determine whether this increase in serum
IL-17A levels plasma has a pathogenic role in autism.
The role of anti- IL-17A therapy in autism should also
be studied.
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